The GLP-1 receptor agonists decrease HbA 1c by stimulating glucose-dependent insulin secretion and by reducing glucagon secretion, gastric emptying, and appetite. 4,5 GLP-1 receptor agonist treatment ...

Emerging data, mostly from China, are included within this guideline for several new therapy options, including the orally administered antiantiangiogenic TKI apatinib (also called rivoceranib), ...

In 50 kidney transplant recipients, GLP-1 receptor agonist use led to a mean weight loss of 3 kg, a mean improvement in estimated glomerular filtration rate of 3·5 mL/min per 1·73 m 2, a median ...

We report a novel chemical class of potent oxytocin receptor antagonists showing a high degree of selectivity against the closely related vasopressin receptors (V1a, V1b, V2). An initial compound, 7, ...

Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, ...

Vasopressin V1a and V1b receptor antagonism does not affect the efficacy of tolvaptan in Polycystic Kidney Disease. American journal of physiology. Renal physiology, 10.1152/ajprenal.00350.2024.

Understanding olfactory receptor (OR)–odorant interaction is crucial for unraveling the molecular intricacies of smell, a sense that is essential for health and survival and has potential therapeutic ...